MacroGenics Company Insiders
| MGNX Stock | USD 15.41 0.20 1.28% |
Slightly above 63% of MacroGenics' corporate insiders are selling. The analysis of the overall insider sentiment regarding MacroGenics suggests that many insiders are alarmed. MacroGenics employs about 339 people. The company is managed by 21 executives with a total tenure of roughly 228 years, averaging almost 10.0 years of service per executive, having 16.14 employees per reported executive.
| Scott Koenig CEO President CEO, Director |
| Paulo Costa Chairman Independent Chairman of the Board |
MacroGenics' Insider Buying Vs Selling
37
Selling | Buying |
Latest Trades
| 2024-04-04 | Jeffrey Stuart Peters | Disposed 51395 @ 15.55 | View | ||
| 2024-02-26 | Jeffrey Stuart Peters | Disposed 16124 @ 17.22 | View | ||
| 2024-02-01 | Ezio Bonvini | Disposed 13316 @ 15 | View | ||
| 2024-01-19 | Ezio Bonvini | Disposed 13316 @ 12 | View | ||
| 2023-12-20 | Ezio Bonvini | Disposed 18880 @ 10.08 | View | ||
| 2023-10-02 | Target N V Biotech | Acquired 150000 @ 4.46 | View | ||
| 2023-09-07 | Target N V Biotech | Acquired 200000 @ 5.26 | View | ||
| 2023-08-30 | Edward Hurwitz | Acquired 15000 @ 4.91 | View |
Monitoring MacroGenics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
MacroGenics |
MacroGenics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with MacroGenics' future performance. Based on our forecasts, it is anticipated that MacroGenics will maintain a workforce of slightly above 340 employees by May 2024.MacroGenics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3633) % which means that it has lost $0.3633 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0615) %, meaning that it created substantial loss on money invested by shareholders. MacroGenics' management efficiency ratios could be used to measure how well MacroGenics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.03 in 2024. Return On Capital Employed is likely to rise to -0.66 in 2024. Net Tangible Assets is likely to rise to about 245.6 M in 2024, whereas Total Assets are likely to drop slightly above 287.5 M in 2024.Common Stock Shares Outstanding is likely to drop to about 42.1 M in 2024. Net Loss is likely to drop to about (113.2 M) in 2024
MacroGenics Workforce Comparison
MacroGenics is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 2,416. MacroGenics retains roughly 339 in number of employees claiming about 14% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (4.6) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $4.6. MacroGenics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MacroGenics insiders, such as employees or executives, is commonly permitted as long as it does not rely on MacroGenics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MacroGenics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.8649 | 32 | 37 | 1,397,445 | 608,699 |
| 2023-12-01 | 1.0 | 1 | 1 | 150,000 | 18,880 |
| 2023-03-01 | 4.4 | 22 | 5 | 2,867,125 | 30,494 |
| 2022-12-01 | 8.0 | 8 | 1 | 1,662,899 | 8,500 |
| 2022-06-01 | 5.3333 | 16 | 3 | 384,145 | 59,931 |
| 2022-03-01 | 11.0 | 11 | 1 | 1,369,216 | 500.00 |
| 2021-12-01 | 2.0 | 2 | 1 | 202,540 | 2,540 |
| 2021-09-01 | 2.5 | 5 | 2 | 805,000 | 10,000 |
| 2021-06-01 | 2.1429 | 15 | 7 | 406,076 | 43,492 |
| 2021-03-01 | 2.0 | 12 | 6 | 932,749 | 68,415 |
| 2020-12-01 | 0.5 | 3 | 6 | 2,500 | 5,000 |
| 2020-09-01 | 0.4737 | 9 | 19 | 236,862 | 122,928 |
| 2020-06-01 | 1.0769 | 14 | 13 | 137,532 | 39,064 |
| 2020-03-01 | 1.6 | 16 | 10 | 1,036,289 | 158,412 |
| 2019-09-01 | 1.0 | 1 | 1 | 1,662 | 1,662 |
| 2019-06-01 | 3.0 | 12 | 4 | 95,973 | 8,000 |
| 2019-03-01 | 1.4545 | 16 | 11 | 854,728 | 78,490 |
| 2018-12-01 | 1.0 | 6 | 6 | 60,000 | 60,000 |
| 2018-03-01 | 1.0 | 20 | 20 | 682,483 | 96,055 |
| 2017-12-01 | 0.6667 | 4 | 6 | 38,000 | 33,000 |
| 2017-09-01 | 0.8 | 4 | 5 | 60,264 | 72,264 |
| 2017-06-01 | 2.0 | 10 | 5 | 96,057 | 41,862 |
| 2017-03-01 | 6.0 | 12 | 2 | 697,898 | 84,898 |
| 2016-12-01 | 0.5714 | 4 | 7 | 31,580 | 55,574 |
| 2016-09-01 | 1.0 | 6 | 6 | 108,922 | 63,343 |
| 2016-06-01 | 1.0 | 9 | 9 | 167,691 | 133,832 |
| 2016-03-01 | 1.5556 | 14 | 9 | 150,128 | 89,301 |
| 2015-12-01 | 0.9375 | 15 | 16 | 468,083 | 94,505 |
| 2015-09-01 | 0.9286 | 13 | 14 | 67,615 | 85,321 |
| 2015-06-01 | 0.9444 | 17 | 18 | 132,197 | 119,212 |
| 2015-03-01 | 0.5 | 1 | 2 | 5,000 | 10,000 |
| 2014-12-01 | 0.8966 | 26 | 29 | 576,904 | 383,108 |
| 2014-09-01 | 0.3333 | 1 | 3 | 5,000 | 18,316 |
| 2014-06-01 | 1.6 | 8 | 5 | 58,566 | 27,239 |
| 2014-03-01 | 0.2 | 1 | 5 | 13,849 | 645,670 |
| 2013-12-01 | 1.0588 | 36 | 34 | 11,720,708 | 189,213,131 |
MacroGenics Notable Stakeholders
A MacroGenics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MacroGenics often face trade-offs trying to please all of them. MacroGenics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MacroGenics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Scott MD | CEO President | Profile | |
| Scott Koenig | President CEO, Director | Profile | |
| Paulo Costa | Independent Chairman of the Board | Profile | |
| Kathryn Stein | Senior Vice President- Product Development & Regulatory Affairs | Profile | |
| Ezio Bonvini | Senior Vice President- Research | Profile | |
| Jon Wigginton | Senior Vice President - Clinical Development | Profile | |
| Thomas Spitznagel | Senior Vice President - Bio Pharmaceutical Development and Manufacturing | Profile | |
| Jeffrey Peters | Vice President General Counsel | Profile | |
| James Karrels | CFO, Sr. VP and Corporate Secretary | Profile | |
| Eric Risser | Sr. VP of Bus. Devel. and Portfolio Management | Profile | |
| Atul Saran | Sr. VP and General Counsel | Profile | |
| David Stump | Independent Director | Profile | |
| Jay Siegel | Director | Profile | |
| Scott Jackson | Director | Profile | |
| Matthew Fust | Independent Director | Profile | |
| Karen Ferrante | Director | Profile | |
| Edward Hurwitz | Independent Director | Profile | |
| Kenneth Galbraith | Independent Director | Profile | |
| Lynn Cilinski | Principal Accounting Officer, VP, Controller and Treasurer | Profile | |
| Christopher MD | VP Communications | Profile | |
| Ezio MD | Senior Officer | Profile |
About MacroGenics Management Performance
The success or failure of an entity such as MacroGenics often depends on how effective the management is. MacroGenics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MacroGenics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MacroGenics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.69) | (0.66) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.06) | (0.06) |
The data published in MacroGenics' official financial statements usually reflect MacroGenics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of MacroGenics. For example, before you start analyzing numbers published by MacroGenics accountants, it's critical to develop an understanding of what MacroGenics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of MacroGenics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MacroGenics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in MacroGenics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MacroGenics. Please utilize our Beneish M Score to check the likelihood of MacroGenics' management manipulating its earnings.
MacroGenics Workforce Analysis
Traditionally, organizations such as MacroGenics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MacroGenics within its industry.MacroGenics Manpower Efficiency
Return on MacroGenics Manpower
| Revenue Per Employee | 173.3K | |
| Revenue Per Executive | 2.8M | |
| Net Loss Per Employee | 26.7K | |
| Net Loss Per Executive | 431.3K | |
| Working Capital Per Employee | 575.9K | |
| Working Capital Per Executive | 9.3M |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for MacroGenics Stock analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is MacroGenics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MacroGenics. If investors know MacroGenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MacroGenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.949 | Quarterly Revenue Growth (0.85) | Return On Assets (0.36) | Return On Equity (0.06) |
The market value of MacroGenics is measured differently than its book value, which is the value of MacroGenics that is recorded on the company's balance sheet. Investors also form their own opinion of MacroGenics' value that differs from its market value or its book value, called intrinsic value, which is MacroGenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MacroGenics' market value can be influenced by many factors that don't directly affect MacroGenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MacroGenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if MacroGenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MacroGenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.